Researchers reported a bioengineered viral platform that delivers RNA‑editing machinery to macrophages in vivo, enabling targeted editing within the immune cells of living organisms as a therapeutic strategy against sepsis. The work, published in Nature Communications, couples chemogenetic control with viral delivery to modulate innate immune responses during overwhelming infection. The study demonstrated proof‑of‑concept editing activity in macrophages and therapeutic benefit in preclinical sepsis models. Authors emphasized macrophage tropism and safety controls embedded in the platform; further translational steps will require detailed biodistribution, immunogenicity and long‑term safety studies. Biotech developers and translational researchers will view this as an important preclinical milestone for in vivo RNA therapeutics that target immune cells rather than parenchymal tissues.